BioNumerik Pharmaceuticals, Inc.

Patent Applications and Registrations

Patent applications and USPTO patent grants for BioNumerik Pharmaceuticals, Inc..The latest application filed is for "increasing cancer patient survival time by administration of dithio-containing compounds".

Company Profile

5.46.31

BioNumerik Pharmaceuticals, Inc. - San Antonio unknown UNKNOWN
BioNumerik Pharmaceuticals, Inc. -

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Trademarks

Patent Activity

Patent	Date
Administration of karenitecin for the treatment of platinum and/or taxane chemotherapy-resistant or -refractory advanced ovarian cancer Grant 10,413,538 - Hausheer Sept	2019-09-17
Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds App 20180369173 - Hausheer; Frederick H.	2018-12-27
Contemporaneous, Heterogeneously-oriented, Multi-targeted Therapeutic Modification And/or Modulation Of Disease By Administration Of Sulfur-containing, Amino Acid-specific Small Molecules App 20170007561 - Hausheer; Frederick H.	2017-01-12
Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds App 20160287539 - Hausheer; Frederick H.	2016-10-06
Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds App 20160287540 - Hausheer; Frederick H.	2016-10-06
Compositions and methods of use of compounds to increase cancer patient survival time Grant 9,320,760 - Hausheer April 26, 2	2016-04-26
Pneumatic Tourniquet App 20160106439 - Menashe; Shaked	2016-04-21
Administration Of Karenitecin For The Treatment Of Advanced Ovarian Cancer, Including Chemotherapy-resistant And/or The Mucinous Adenocarcinoma Sub-types App 20160038519 - Hausheer; Frederick H.	2016-02-11
Increasing cancer patient survival time by administration of dithio-containing compounds Grant 9,023,805 - Hausheer May 5, 2	2015-05-05
Administration of Karenitecin for the Treatment of Platinum and/or Taxane Chemotherapy-Resistant or -Refractory Advanced Ovarian Cancer App 20140336150 - Frederick; Hausheer H.	2014-11-13
Methods For The Total Chemical Synthesis Of Enantiomerically-pure 7-(2'-trimethylsilyl) Ethyl Camptothecin App 20140135499 - Chen; Xinghai ; et al.	2014-05-15
Methods for the total chemical synthesis of enantiomerically-pure 7-(2'-trimethylsilyl)ethyl camptothecin Grant 8,722,886 - Chen , et al. May 13, 2	2014-05-13
Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity Grant 8,710,095 - Hausheer April 29, 2	2014-04-29
Deuterated analogs of (4S)-4-ethyl-4-hydroxy-11-[2- (trimethylsilyl)ethyl]-1H-pyrano[3', 4':6,7] indolizino [1,2-b]quinoline-3,14(4H, 12H)-dione and methods of use thereof Grant 8,569,265 - Chen , et al. October 29, 2	2013-10-29
Deuterated analogs of (4S)-4-Ethyl-4-hydroxy-11-[2- (trimethylsilyl)ethyl]-1H-pyrano[3', 4':6,7] indolizino [1,2-b]quinoline-3,14(4H, 12H)-dione and methods of use thereof App 20120282261 - Chen; Xinghai ; et al.	2012-11-08
Chemoprotective methods Grant 8,143,236 - Hausheer March 27, 2	2012-03-27
Increasing cancer patient survival time by administration of dithio-containing compounds App 20120070404 - Hausheer; Frederick H.	2012-03-22
Chemoprotective methods and compositions Grant 8,026,227 - Hausheer September 27, 2	2011-09-27
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents Grant 7,829,117 - Hausheer , et al. November 9, 2	2010-11-09
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents Grant 7,829,538 - Hausheer , et al. November 9, 2	2010-11-09
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents Grant 7,829,541 - Hausheer , et al. November 9, 2	2010-11-09
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents Grant 7,829,540 - Hausheer , et al. November 9, 2	2010-11-09
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents Grant 7,829,539 - Hausheer , et al. November 9, 2	2010-11-09
Platinum analogs with bis-nitrile-containing ligands Grant 7,777,060 - Chen , et al. August 17, 2	2010-08-17
Monoazole ligand platinum analogs Grant 7,759,488 - Xiao , et al. July 20, 2	2010-07-20
Camptothecin-analog with a novel, "flipped" lactone-stable, E-ring and methods for making and using same Grant 7,687,487 - Hausheer March 30, 2	2010-03-30
C10-substituted camptothecin analogs Grant 7,687,497 - Narkunan , et al. March 30, 2	2010-03-30
C7-substituted camptothecin analogs Grant 7,687,496 - Narkunan , et al. March 30, 2	2010-03-30
Compositions and methods of use of compounds to increase cancer patient survival time App 20090232827 - Hausheer; Frederick H.	2009-09-17
Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions App 20090232906 - Hausheer; Frederick H.	2009-09-17
Platinum complexes with mononitrile-containing ligands Grant 7,569,606 - Xiao , et al. August 4, 2	2009-08-04
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents App 20090111735 - Hausheer; Frederick H. ; et al.	2009-04-30
C10-substituted camptothecin analogs App 20090099166 - Narkunan; Kesavaram ; et al.	2009-04-16
C7- substituted camptothecin analogs App 20090099224 - Narkunan; Kesavaram ; et al.	2009-04-16
Camptothecin-analog with a novel, "flipped" lactone-stable, E-ring and methods for making and using same App 20080261919 - Hausheer; Frederick H.	2008-10-23
Platinum analogs with bis-nitrile-containing ligands App 20080194680 - Chen; Xinghai ; et al.	2008-08-14
Chemoprotective methods and compositions App 20080193498 - Hausheer; Frederick H.	2008-08-14
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents App 20080161525 - Hausheer; Frederick H. ; et al.	2008-07-03
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents App 20080161415 - Hausheer; Frederick H. ; et al.	2008-07-03
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents App 20080161603 - Hausheer; Frederick H. ; et al.	2008-07-03
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents App 20080161414 - Hausheer; Frederick H. ; et al.	2008-07-03
Medicinal disulfide salts Grant 7,282,602 - Huang , et al. October 16, 2	2007-10-16
Anti-cancer activity augmentation compounds and formulations and methods of use thereof App 20070219268 - Hausheer; Frederick H.	2007-09-20
Monoimine ligand platinum analogs Grant 7,268,244 - Hausheer , et al. September 11, 2	2007-09-11
Platinum complexes with mononitrile-containing ligands Grant 7,238,823 - Xiao , et al. July 3, 2	2007-07-03
Chemoprotective methods and compositions App 20070135519 - Hausheer; Frederick H.	2007-06-14
Method for treating patients for radiation exposure Grant 7,176,192 - Hausheer February 13, 2	2007-02-13
Process for synthesizing 6-quinazolinyl-ethyl-benzoyl and related antifolates Grant 7,060,825 - Wu , et al. June 13, 2	2006-06-13
Process for synthesizing disulfides Grant 7,053,240 - Kawami , et al. May 30, 2	2006-05-30
Process For Making Camptothecin Derivatives App 20060094876 - Wu; Ye ; et al.	2006-05-04
Pharmaceutical formulations of camptothecins and process for making same App 20060094692 - Hausheer; Frederick H. ; et al.	2006-05-04
Process for making camptothecin derivatives Grant 7,030,243 - Wu , et al. April 18, 2	2006-04-18
Process for synthesizing L-.gamma.-methylene glutamic acid and analogs Grant 6,977,311 - Kochat , et al. December 20, 2	2005-12-20
Method for preparing disodium 2,2'-dithiobis(ethanesulphonate) Grant 6,936,733 - Cazaux , et al. August 30, 2	2005-08-30
Process for synthesizing disulfides App 20050137419 - Kawami, Koh ; et al.	2005-06-23
Process for making camptothecin derivatives Grant 6,723,849 - Narkunan , et al. April 20, 2	2004-04-20
Method of treating septic shock Grant 6,197,831 - Hausheer March 6, 2	2001-03-06
Formulations and methods of reducing toxicity of antineoplastic agents Grant 6,066,668 - Hausheer , et al. May 23, 2	2000-05-23
Formulations and methods of reducing toxicity of antineoplastic agents Grant 6,057,361 - Hausheer , et al. May 2, 2	2000-05-02
Highly lipophilic Camptothecin derivatives Grant 6,057,303 - Haridas , et al. May 2, 2	2000-05-02
Formulations and methods of reducing toxicity of antineoplastic agents Grant 6,040,294 - Hausheer , et al. March 21, 2	2000-03-21
Formulations and methods of reducing toxicity of antineoplastic agents Grant 6,040,312 - Hausheer , et al. March 21, 2	2000-03-21
Pharmaceutical formulations of taxanes Grant 6,040,330 - Hausheer , et al. March 21, 2	2000-03-21
Formulations and methods of reducing toxicity of antineoplastic agents Grant 5,919,816 - Hausheer , et al. July 6, 1	1999-07-06
Highly lipophilic camptothecin derivatives Grant 5,910,491 - Hausheer , et al. June 8, 1	1999-06-08
Formulations and compositions of poorly water soluble camptothecin derivatives Grant 5,900,419 - Hausheer , et al. May 4, 1	1999-05-04
Formulations and compositions of poorly water soluble camptothecin derivatives Grant 5,859,022 - Hausheer , et al. January 12, 1	1999-01-12
Process for making mesna, dimesna and derivatives thereof Grant 5,808,140 - Haridas September 15, 1	1998-09-15
Formulations and compositions of poorly water soluble camptothecin derivatives Grant 5,726,181 - Hausheer , et al. March 10, 1	1998-03-10
Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof Grant 5,674,873 - Hausheer , et al. October 7, 1	1997-10-07
11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof Grant 5,468,754 - Hausheer , et al. November 21, 1	1995-11-21
Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof Grant 5,447,936 - Hausheer , et al. September 5, 1	1995-09-05

Company Registrations

NCAGE Code	62ZU8	BIONUMERIK PHARMACEUTICALS INC.
CAGE Code	62ZU8	BIONUMERIK PHARMACEUTICALS, INC.
SEC	0000895131	BioNumerik Pharmaceuticals, Inc. of TEXAS

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.